NeuroSense Releases Long-Term Survival Data from ALS Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy NRSN?
NeuroSense Therapeutics announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis, or ALS. The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in overall survival for patients treated with PrimeC, compared to those initially assigned to placebo. According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved an estimated median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo during the double-blind phase and crossing over to active treatment during the open label extension. This represents over 14-month improvement and approximately a 70% increase in median survival. The survival benefit was sustained over time, with consistent separation between treatment arms throughout the follow-up period. The PARADIGM Phase 2b trial was a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of PrimeC in 68 people living with ALS. Participants were administered PrimeC or placebo at a 2:1 ratio, respectively, for the six-month double-blind part. NeuroSense continues to engage with regulatory authorities regarding the advancement of PrimeC into pivotal late-stage development and believes these findings add important long-term clinical context to previously reported efficacy results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRSN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRSN
Wall Street analysts forecast NRSN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.741
Low
7.50
Averages
8.25
High
9.00
Current: 0.741
Low
7.50
Averages
8.25
High
9.00
About NRSN
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeuroSense to Present PrimeC Data at AD/PD 2026 Conference
- Clinical Data Presentation: Dr. Christian Lunetta, Chief Medical Officer of NeuroSense, will present new clinical and biomarker data on PrimeC at the 2026 AD/PD International Conference, highlighting its potential in ALS treatment and likely attracting significant attention from the scientific community.
- PARADIGM Trial Findings: The presentation will review key findings from the Phase 2b PARADIGM trial, which provide an important scientific foundation for the design of the global Phase 3 PARAGON trial, potentially accelerating the path to market authorization for PrimeC.
- ALS Disease Burden: Over 5,000 people are diagnosed with ALS annually in the U.S., with the number of patients expected to grow by 24% by 2040, underscoring NeuroSense's strategic importance in addressing this significant unmet medical need.
- Global Trial Plans: The PARAGON Phase 3 trial is planned as a multinational, randomized, double-blind, placebo-controlled study designed to further evaluate PrimeC's potential to slow disease progression in ALS patients, demonstrating NeuroSense's commitment to advancing innovative therapeutic options.
See More
NeuroSense Publishes ALS Clinical Trial Results in JAMA Neurology
- Clinical Trial Results: NeuroSense's PARADIGM Phase 2b trial results indicate that the PrimeC treatment group achieved a 7.92-point improvement in functional scores over 18 months, representing over a 36% slowdown in disease progression, laying a solid foundation for further Phase 3 trials.
- Biomarker Changes: The trial observed significant improvements in iron metabolism biomarkers, including the preservation of transferrin levels and stabilization of ferritin, indicating PrimeC's effectiveness in modulating ALS-related biological pathways.
- Safety and Tolerability: The study results demonstrated good safety for PrimeC, with multiple clinical endpoints consistently suggesting potential clinical benefits, thereby enhancing confidence in its role as a disease-modifying therapy.
- Future Development Plans: NeuroSense has received FDA clearance to proceed with a Phase 3 trial aimed at validating PrimeC's impact on ALS patients, further advancing its clinical development trajectory.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Dynamics: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering purchasing MSTR stock should pay attention to the latest insights from analysts to make more informed investment choices.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a comprehensive market perspective.
See More
NeuroSense Reports New ALS Treatment Data
- Significant Survival Improvement: The recently reported long-term survival data from the Phase 2b PARADIGM trial shows that PrimeC achieves a 65% reduction in the risk of death (hazard ratio: 0.35; p=0.0037) and offers a median survival benefit of over 14 months (36.3 months vs. 21.4 months; log-rank p=0.0218), providing a hopeful outlook for ALS treatment.
- Clinical Data Presentation: This data will be presented by ALS research expert Dr. Jinsy Andrews at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference on March 9, 2026, further reinforcing PrimeC's clinical efficacy and safety in ALS treatment.
- Regulatory Progress Acceleration: With the release of long-term survival data, NeuroSense is actively engaging with regulatory authorities to advance PrimeC toward potential marketing authorization, marking a strategic advancement in the ALS treatment landscape.
- Market Potential: Over 5,000 new ALS diagnoses occur annually in the U.S., with an expected 24% increase in patients by 2040, presenting a significant market opportunity for NeuroSense's PrimeC, especially in the context of limited effective treatment options currently available.
See More
NeuroSense Releases New ALS Treatment Data
- Significant Survival Improvement: In the PARADIGM Phase 2b trial, ALS patients treated with PrimeC achieved a median survival of 36.3 months, compared to 21.4 months for the placebo group, representing over a 14-month improvement and approximately a 70% increase in survival, highlighting PrimeC's potential in ALS treatment.
- Statistical Significance Confirmed: The log-rank test for survival curves yielded a p-value of 0.0218, indicating a statistically significant difference in survival between the PrimeC and placebo groups, further validating the clinical efficacy of PrimeC.
- Risk Reduction Notable: Analysis using a Cox proportional hazards model revealed that PrimeC treatment was associated with a 65% reduction in the risk of death (hazard ratio: 0.35), providing strong support for its potential as a disease-modifying therapy that could transform ALS patient treatment outcomes.
- Broad Clinical Development Prospects: NeuroSense is actively engaging with regulatory authorities to advance PrimeC into pivotal late-stage development, with the new survival data adding important long-term clinical context that enhances its competitive position in the market.
See More
NeuroSense Secures Australian Patent, Strengthening Global IP for PrimeC
- Global IP Expansion: NeuroSense has secured Australian Patent No. 2022370513, further enhancing global intellectual property protection for PrimeC, with patent coverage extending through 2042, demonstrating the company's strategic positioning in key markets.
- Support from US Patent: The grant of this patent follows the approval of US Patent 12,097,185, indicating that NeuroSense's intellectual property protection strategy is progressing steadily in critical markets, thereby strengthening its competitive edge.
- PrimeC Drug Development: PrimeC is a fixed-dose oral therapy combining ciprofloxacin and celecoxib, designed to combat ALS and Alzheimer's disease through a multi-target mechanism, showcasing its potential in clinical stages.
- Addressing Market Demand: With the number of ALS patients expected to grow by 24% by 2040, NeuroSense's IP protection and the development of PrimeC will help meet the increasing market demand, driving long-term value creation.
See More
NeuroSense to Present PrimeC Data at AD/PD 2026 Conference
- Clinical Data Presentation: Dr. Christian Lunetta, Chief Medical Officer of NeuroSense, will present new clinical and biomarker data on PrimeC at the 2026 AD/PD International Conference, highlighting its potential in ALS treatment and likely attracting significant attention from the scientific community.
- PARADIGM Trial Findings: The presentation will review key findings from the Phase 2b PARADIGM trial, which provide an important scientific foundation for the design of the global Phase 3 PARAGON trial, potentially accelerating the path to market authorization for PrimeC.
- ALS Disease Burden: Over 5,000 people are diagnosed with ALS annually in the U.S., with the number of patients expected to grow by 24% by 2040, underscoring NeuroSense's strategic importance in addressing this significant unmet medical need.
- Global Trial Plans: The PARAGON Phase 3 trial is planned as a multinational, randomized, double-blind, placebo-controlled study designed to further evaluate PrimeC's potential to slow disease progression in ALS patients, demonstrating NeuroSense's commitment to advancing innovative therapeutic options.
See More
NeuroSense Publishes ALS Clinical Trial Results in JAMA Neurology
- Clinical Trial Results: NeuroSense's PARADIGM Phase 2b trial results indicate that the PrimeC treatment group achieved a 7.92-point improvement in functional scores over 18 months, representing over a 36% slowdown in disease progression, laying a solid foundation for further Phase 3 trials.
- Biomarker Changes: The trial observed significant improvements in iron metabolism biomarkers, including the preservation of transferrin levels and stabilization of ferritin, indicating PrimeC's effectiveness in modulating ALS-related biological pathways.
- Safety and Tolerability: The study results demonstrated good safety for PrimeC, with multiple clinical endpoints consistently suggesting potential clinical benefits, thereby enhancing confidence in its role as a disease-modifying therapy.
- Future Development Plans: NeuroSense has received FDA clearance to proceed with a Phase 3 trial aimed at validating PrimeC's impact on ALS patients, further advancing its clinical development trajectory.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Dynamics: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering purchasing MSTR stock should pay attention to the latest insights from analysts to make more informed investment choices.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a comprehensive market perspective.
See More
NeuroSense Reports New ALS Treatment Data
- Significant Survival Improvement: The recently reported long-term survival data from the Phase 2b PARADIGM trial shows that PrimeC achieves a 65% reduction in the risk of death (hazard ratio: 0.35; p=0.0037) and offers a median survival benefit of over 14 months (36.3 months vs. 21.4 months; log-rank p=0.0218), providing a hopeful outlook for ALS treatment.
- Clinical Data Presentation: This data will be presented by ALS research expert Dr. Jinsy Andrews at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference on March 9, 2026, further reinforcing PrimeC's clinical efficacy and safety in ALS treatment.
- Regulatory Progress Acceleration: With the release of long-term survival data, NeuroSense is actively engaging with regulatory authorities to advance PrimeC toward potential marketing authorization, marking a strategic advancement in the ALS treatment landscape.
- Market Potential: Over 5,000 new ALS diagnoses occur annually in the U.S., with an expected 24% increase in patients by 2040, presenting a significant market opportunity for NeuroSense's PrimeC, especially in the context of limited effective treatment options currently available.
See More
NeuroSense Releases New ALS Treatment Data
- Significant Survival Improvement: In the PARADIGM Phase 2b trial, ALS patients treated with PrimeC achieved a median survival of 36.3 months, compared to 21.4 months for the placebo group, representing over a 14-month improvement and approximately a 70% increase in survival, highlighting PrimeC's potential in ALS treatment.
- Statistical Significance Confirmed: The log-rank test for survival curves yielded a p-value of 0.0218, indicating a statistically significant difference in survival between the PrimeC and placebo groups, further validating the clinical efficacy of PrimeC.
- Risk Reduction Notable: Analysis using a Cox proportional hazards model revealed that PrimeC treatment was associated with a 65% reduction in the risk of death (hazard ratio: 0.35), providing strong support for its potential as a disease-modifying therapy that could transform ALS patient treatment outcomes.
- Broad Clinical Development Prospects: NeuroSense is actively engaging with regulatory authorities to advance PrimeC into pivotal late-stage development, with the new survival data adding important long-term clinical context that enhances its competitive position in the market.
See More
NeuroSense Secures Australian Patent, Strengthening Global IP for PrimeC
- Global IP Expansion: NeuroSense has secured Australian Patent No. 2022370513, further enhancing global intellectual property protection for PrimeC, with patent coverage extending through 2042, demonstrating the company's strategic positioning in key markets.
- Support from US Patent: The grant of this patent follows the approval of US Patent 12,097,185, indicating that NeuroSense's intellectual property protection strategy is progressing steadily in critical markets, thereby strengthening its competitive edge.
- PrimeC Drug Development: PrimeC is a fixed-dose oral therapy combining ciprofloxacin and celecoxib, designed to combat ALS and Alzheimer's disease through a multi-target mechanism, showcasing its potential in clinical stages.
- Addressing Market Demand: With the number of ALS patients expected to grow by 24% by 2040, NeuroSense's IP protection and the development of PrimeC will help meet the increasing market demand, driving long-term value creation.
See More
